GW Pharmaceuticals plc Reports Third Quarter 2020 Financial Results and Operational Progress

By Dr. Matthew Watson

- Total revenue increased 51 percent to $137.1 million – - Epidiolex for seizures associated with TSC launched in the U.S. -- Nabiximols Phase 3 program in MS spasticity now recruiting -- Conference call today at 8:30 a.m. EST -

Read more:
GW Pharmaceuticals plc Reports Third Quarter 2020 Financial Results and Operational Progress

Related Post


categoriaGlobal News Feed commentoComments Off on GW Pharmaceuticals plc Reports Third Quarter 2020 Financial Results and Operational Progress | dataNovember 3rd, 2020

About...

This author published 5852 posts in this site.

Share

FacebookTwitterEmailWindows LiveTechnoratiDeliciousDiggStumbleponMyspaceLikedin

Comments are closed.





Personalized Gene Medicine | Mesenchymal Stem Cells | Stem Cell Treatment for Multiple Sclerosis | Stem Cell Treatments | Board Certified Stem Cell Doctors | Stem Cell Medicine | Personalized Stem Cells Therapy | Stem Cell Therapy TV | Individual Stem Cell Therapy | Stem Cell Therapy Updates | MD Supervised Stem Cell Therapy | IPS Stem Cell Org | IPS Stem Cell Net | Genetic Medicine | Gene Medicine | Longevity Medicine | Immortality Medicine | Nano Medicine | Gene Therapy MD | Individual Gene Therapy | Affordable Stem Cell Therapy | Affordable Stem Cells | Stem Cells Research | Stem Cell Breaking Research

Copyright :: 2024